Krystal Biotech Q3 revenue improves 30% to $127.3m
Pontos principais
- Krystal Biotech reported third-quarter VYJUVEK revenue of $127.3 million, up 30% year over year, with a gross margin of 94%.
- Net income declined to $63.1 million from $79.4 million, while cash and investments totalled $1.2 billion.
- The board authorized up to $400 million in share repurchases, while the company advanced European commercialization and its clinical development programmes.
Krystal Biotech (NASDAQ:KRYS) reported third-quarter 2026 VYJUVEK net revenue of $127.3 million, up 30% year over year, while maintaining a gross margin of 94%.
Despite higher product revenue, net income declined to $63.1 million from $79.4 million, while diluted earnings per share fell to $2.05 from $2.66.
The company reported that VYJUVEK continued generating revenue growth, while its board authorized a share repurchase programme of up to $400 million.
Cash and investments totalled $1.2 billion at September 30, while pricing negotiations for VYJUVEK concluded in Germany and Italy, with an Italian commercial launch expected in early 2027.
Krystal authorized up to $400 million in share repurchases and expects combined research, development and administrative expenses, excluding stock-based compensation, of $155 million–$165 million for 2026.
In a three-patient KB113 study, more than 80% of assessed basal cell carcinoma lesions showed clinical regression, while enrolment in the KB801 programme progressed more slowly than anticipated, with results now expected in 2027.
Krystal also expects the final patient visit in its KB803 programme in February 2027, with results anticipated shortly afterwards, as it continues developing its gene therapy portfolio beyond VYJUVEK.
